流感季爆火的居家快检，真的有那么灵？

商业秀

2025/12/23

千亿市场博弈下爆火的居家快检，是救命神器还是踩坑陷阱？/文｜何阑伊编｜杨肖若出品｜商业秀图片来源｜由AI生成凌晨两点的北京，王女士抱着烧到39℃的孩子急得直跺脚。医院发热门诊数小时的长队、未知的交叉感染风险，让此时着急的她果断打开美团买药，下单了流感居家快检。2点40分采样盒敲门，5分钟搞定鼻拭子，清晨5点收到甲流阳性报告，线上问诊开方后，7点奥司他韦就送上门，孩子当天下午就退了烧。这场深夜育儿...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2593466914"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2593466914\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2593466914?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-12-23 10:27","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2593466914","market":"hk","top_or_hot":-1,"title":"流感季爆火的居家快检，真的有那么灵？","media":"商业秀","content":"<div>\n<p>千亿市场博弈下爆火的居家快检，是救命神器还是踩坑陷阱？/文｜何阑伊编｜杨肖若出品｜商业秀图片来源｜由AI生成凌晨两点的北京，王女士抱着烧到39℃的孩子急得直跺脚。医院发热门诊数小时的长队、未知的交叉感染风险，让此时着急的她果断打开美团买药，下单了流感居家快检。2点40分采样盒敲门，5分钟搞定鼻拭子，清晨5点收到甲流阳性报告，线上问诊开方后，7点奥司他韦就送上门，孩子当天下午就退了烧。这场深夜育儿...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223122533a6c43f1d&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>流感季爆火的居家快检，真的有那么灵？</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n流感季爆火的居家快检，真的有那么灵？\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-23 10:27 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223122533a6c43f1d&s=b><strong>商业秀</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>千亿市场博弈下爆火的居家快检，是救命神器还是踩坑陷阱？/文｜何阑伊编｜杨肖若出品｜商业秀图片来源｜由AI生成凌晨两点的北京，王女士抱着烧到39℃的孩子急得直跺脚。医院发热门诊数小时的长队、未知的交叉感染风险，让此时着急的她果断打开美团买药，下单了流感居家快检。2点40分采样盒敲门，5分钟搞定鼻拭子，清晨5点收到甲流阳性报告，线上问诊开方后，7点奥司他韦就送上门，孩子当天下午就退了烧。这场深夜育儿...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223122533a6c43f1d&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1328277881.USD","symbol_name":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223122533a6c43f1d&s=b","article_id":"2593466914","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223122533a6c43f1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2593466914","pubTimestamp":1766456879,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"流感检测需求激增，近一周，美团买药居家快检服务订单量环比增长超60%，上海等核心城市订单创年内新高，亲子用户占了七成。一边是缓解医疗挤兑的创新尝试，一边是频繁出现的检测误差，美团买药们力推的居家快检，真的有那么灵吗？目前多数居家快检仅覆盖12种常见病原体，像合胞病毒、腺病毒等高发致病原均未纳入检测范围。另一个容易被忽视的问题是，居家检测后自行用药的风险极高。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"86618":"京东健康-R","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","LU0541502299.USD":"ALLSPRING  EMERGING MARKETS EQUITY \"I\" (USD) ACC","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","SG9999000327.SGD":"Schroder Asian Growth A Dis SGD","LU0823426308.USD":"法巴中国股票基金","LU0828237510.HKD":"SCHRODER ISF BIC (BRAZ IN CH)\"A\" (HKD) ACC","LU0054237671.USD":"FIDELITY ASIAN SPECIAL SITUATIONS \"A\" INC","LU0672654166.SGD":"FTIF - Templeton Asian Growth A (acc) SGD-H1","LU0228659784.USD":"施罗德金砖四国基金","LU0819123356.HKD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (HKD) ACC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU0051755006.USD":"摩根大通中国A (dist)","LU0370786039.SGD":"Fidelity Greater China A-SGD","LU0683595622.HKD":"AB SICAV I-EM.MKTS MUL.ASS.PTF(AD)","LU0828238088.HKD":"SCHRODER ISF GLBL EMGNG MKT OPPS \"A\" (HKD) ACC","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","BK1571":"互联网医疗","LU0543330483.HKD":"TEMPLETON ASIAN GROWTH \"A\" (HKD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1481107354.HKD":"HSBC GIF HONG KONG EQUITY \"AD\" (HKD) INC","LU0449509016.USD":"HSBC GIF BRIC EQUITY \"AC\" (USD) ACC","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0210526637.USD":"JPM CHINA \"A\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00BF5LJ272.USD":"Legg Mason Martin Currie - Global Emerging Markets A Acc USD","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0594300179.USD":"FIDELITY CHINA CONSUMER \"A\" (USD) ACC","LU1868837565.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES \"1\" (USD) ACC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0700851271.USD":"NINETY ONE GSF EMERGING MARKETS MULTI-ASSET \"A\" (USD) ACC","BK1591":"就地过年概念","SG9999001903.USD":"Aberdeen Standard Pacific Equity USD","SGXZ86797644.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) INC","BK1247":"药品零售","BK1583":"高瓴概念","LU0164865239.USD":"HSBC GIF CHINESE EQUITY \"AC\" (USD) ACC","LU0918141887.USD":"安联亚洲实际收益股票基金","LU0084288322.USD":"Natixis Asia Equity RD USD","BK1604":"节假日概念","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU0011963245.USD":"abrdn SICAV I ASIA PACIFIC SUSTAINAB  LE EQUITY \"A\" (USD) ACC","LU0348814723.USD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"A\" (USD) INC  NC","SGXZ62798434.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) ACC","BK1521":"挪威政府全球养老基金持仓","LU0143863784.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES\"DU\" (USD) ACC","LU0165289439.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AC\" ACC","LU0345775950.USD":"NINETY ONE GSF ASIAN EQUITY \"A\" (USD) ACC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","LU1102505929.USD":"FIDELITY SUSTAINABLE EMERGING MARKETS EQUITY  \"A\" (USD) ACC","LU0541501648.USD":"ALLSPRING  EMERGING MARKETS EQUITY \"A\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","LU1323998911.USD":"BGF ASIAN MULTI-ASSET INCOME \"A\" (USD) ACC","LU0737861699.HKD":"FIDELITY CHINA FOCUS \"A \" (HKD) ACC","LU0106252389.USD":"SCHRODER ISF EMERGING MARKETS \"A\" ACC","LU0164880469.USD":"HSBC GIF HONG KONG EQUITY \"AC\" ACC","LU0823426480.USD":"法巴中国股票经典Dis","LU0828237940.HKD":"SCHRODER ISF EMERGING ASIA \"A\" (HKD) ACC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0164872284.USD":"HSBC GIF GLOBAL EMERGING MARKETS EQUITY \"A\" (USD) ACC","LU0577902611.USD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"A\" (USD) ACC","LU0633140560.USD":"AB EMERGING MARKET MULTI ASSET PORTFOLIO \"A\" (USD) ACC","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0143863198.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES\"AU\" (USD) ACC","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","BK1610":"ETF&股票定投概念","SG9999000459.SGD":"Aberdeen Standard Pacific Equity SGD","LU0054450605.USD":"HSBC GIF GLOBAL EMERGING MARKTS EQ \"AD\" INC","SG9999014674.SGD":"Nikko AM All China Equity A SGD","LU0588545904.SGD":"Eastspring Investments - Asian Equity Income ASDM SGD","LU0577902371.SGD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (SGD) ACC","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU0049853897.USD":"SCHRODER ISF EMERGING MARKETS \"A\" (USD) INC AV","LU0588545730.USD":"EASTSPRING INVESTMENTS ASIAN EQUITY INCOME \"ADM\" (USD) INC","BK1575":"同股不同权","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","IE0008368742.USD":"首域中国增长基金I Acc","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","SG9999002463.SGD":"LionGlobal China Growth SGD","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0048597586.USD":"富达亚洲焦点A","IE00B3M56506.USD":"NEUBERGER BERMAN EMERGING MARKETS EQUITY \"A\" (USD) ACC","LU1808992512.USD":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU0633140727.USD":"AB EMERGING MARKETS MULTI ASSET PORTFOLIO \"AD\" (USD) INC","LU1880383440.USD":"AMUNDI FUNDS CHINA EQUITY \"A2\" (USD) INC","LU0531971595.HKD":"HSBC GIF CHINESE EQUITY \"AD\" (HKD) INC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU0588545490.SGD":"Eastspring Investments - Asian Equity Income AS SGD","LU0052750758.USD":"富兰克林中国基金A Acc","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","MPNGY":"美团ADR","LU0611395673.USD":"NINETY ONE GSF EMERGING MARKETS EQUITY \"A\" (USD) ACC","LU1048596156.SGD":"Blackrock Asian Growth Leaders A2 SGD-H","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU0823040885.USD":"东方汇理新兴市场焦点股票基金","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU2152927971.USD":"NORDEA 1 ASIAN STARS EQUITY \"BP\" (USD) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU1675838814.USD":"AB SICAV I - EMERGING MARKETS LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU0315178854.USD":"EASTSPRING INVESTMENTS ASIAN EQUITY INCOME \"A\" ACC","LU0345776255.USD":"NINETY ONE GSF ASIAN EQUITY \"A\" (USD) INC","LU0577902298.EUR":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (EUR) ACC","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","LU0509642566.USD":"SCHRODER ISF GLOBAL EMERGING MARKET OPPORTUNITIES \"A\" (USD) INC AV","HMTD.SI":"Meituan HK SDR 5to1","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0048580855.USD":"富达大中华区A","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU0269904917.USD":"SCHRODER ISF GLOBAL EMERGING MARKET OPPORTUNITIES \"A\" (USD) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0873338254.USD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (USD) INC","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU0577902538.SGD":"Fullerton Lux Funds - Asia Growth and Income Equities A Acc SGD","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","BK1233":"餐馆","LU0348788117.USD":"ALLIANZ EMERGING ASIA EQUITY \"A\" (USD) INC","IE00B29SXG58.USD":"FSSA CHINA FOCUS \"I\" (USD) ACC","LU1188198961.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) INC QV","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU0449515922.USD":"HSBC GIF GLOBAL EMERGING MARKETS EQUITY \"PC\" (USD)ACC","00241":"阿里健康","LU0359201612.USD":"贝莱德中国基金A2","LU0878005551.USD":"UBS (LUX) KEY SELEC ASIA ALLOCATION OPPORTUNITY (USD) \"P\" (USD) ACC","LU1224709979.USD":"FIDELITY CHINA FOCUS \"A\" (USD) ACC","IE0034224299.USD":"PINEBRIDGE ASIA EX JAPAN EQUITY \"A\" (USD) ACC","LU1688375341.USD":"贝莱德中国灵活股票基金","LU1720050803.USD":"安联全方位中国股票基金","LU0605514214.HKD":"FIDELITY CHINA CONSUMER \"A\" (HKD) ACC","LU0348805143.USD":"ALLIANZ ENHANCED ALL CHINA EQUITY \"A\" (USD) INC","LU0797268264.HKD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AT\" (HKD) ACC","BK1515":"抗疫概念","LU0181495838.USD":"施罗德新兴亚洲A Acc","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0214875030.USD":"HSBC GIF BRIC EQUITY \"M2C\" (USD) ACC","LU0149721374.USD":"HSBC GIF HONG KONG EQUITY \"AD\" INC","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","LU0231483743.USD":"abrdn SICAV I - ALL CHINA SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0326948709.USD":"SCHRODER ISF ASIAN TOTAL RETURN \"A\" (USD) ACC","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","LU2087589342.USD":"BGF ASIAN MULTI-ASSET INCOME \"A6\" (USD) INC","LU0823041008.USD":"AMUNDI FUNDS EMERGING WORLD EQUITY \"A2\" (USD) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU0463099449.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) ACC","LU0823039010.USD":"AMUNDI FUNDS ASIA EQUITY FOCUS  \"A2\" (USD) INC","LU1282648689.USD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AMG\" (USD) INC","LU0132412106.USD":"abrdn SICAV I - EMERGING MARKETS EQUITY \"A\" (USD) ACC","LU0823038988.USD":"AMUNDI FUNDS ASIA EQUITY FOCUS  \"A2\" (USD) ACC","LU0348816934.USD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AT\" (USD)","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU0211977185.USD":"EASTSPRING INVESTMENTS GREATER CHINA EQUITY \"A\" ACC","BK1589":"北水核心资产","LU0251144936.SGD":"Fidelity Sustainable Asia Equity A-SGD","BK1618":"Manus概念股","BK1142":"互联网与直销零售","03690":"美团-W","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0499858602.USD":"NINETY ONE GSF ASIA PACIFIC EQUITY OPPORTUNITIES \"A\" (USD) ACC","LU0047713382.USD":"BGF EMERGING MARKETS \"A2\" ACC","LU0261950983.USD":"FIDELITY ASIAN SPECIAL SITUATIONS \"A\" ACC","06618":"京东健康","LU0117841782.USD":"JPM GREATER CHINA \"A\" (USD) INC","LU1102505762.USD":"富达新兴市场焦点 A","LU0593848301.USD":"未来资产亚洲卓越消费股票基金A","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU1868838027.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES \"8\" (USD) ACC","IE0032431581.USD":"PINEBRIDGE GREATER CHINA EQUITY \"A\" (USD) ACC","LU2226246903.HKD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AT4\" (HKD) ACC","LU0173614495.USD":"富达中国焦点A","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0577902454.USD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (USD) ACC","LU1048588211.SGD":"Blackrock Asian Dragon A2 SGD-H","LU0868486357.SGD":"JPMorgan Funds - Emerging Markets Opportunities A (acc) SGD-H","LU0244354667.USD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" ACC","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","BK1615":"港股-互联网","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0594300419.USD":"富达中国消费基金A","LU1770036033.HKD":"NINETY ONE GSF ASIAN EQUITY \"A\" (HKD) ACC","LU0072462343.USD":"贝莱德亚洲巨龙基金","SG9999002828.SGD":"Eastspring Investments Unit Trusts - Dragon Peacock A SGD","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU0650527681.SGD":"Fidelity China Consumer A-SGD","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU1868837722.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES \"2\" (USD) ACC","LU1831875114.USD":"SCHRODER ISF ALL CHINA EQUITY \"A\" (USD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU0589944569.HKD":"ALLIANZ EMERGING ASIA EQUITY \"AT\" (HKD) ACC","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2257852520.SGD":"JPMorgan Funds - Asia Growth A (acc) SGD","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU0320764755.SGD":"FTIF - Templeton Asian Growth A Acc SGD","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0128522157.USD":"TEMPLETON ASIAN GROWTH \"A\" ACC","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0871576103.HKD":"HSBC GIF CHINESE EQUITY \"AC\" (HKD) ACC","LU1105468828.SGD":"Allianz Total Return Asian Equity AM DIS H2-SGD","LU0431992006.USD":"摩根大通新兴市场机会A（acc）","LU0918141705.HKD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AM\" (HKD) INC","LU0865486749.SGD":"Eastspring Investments - Asian Equity Income AS SGD-H","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU0499858438.USD":"NINETY ONE GSF ASIA PACIFIC EQUITY OPPORTUNITIES \"A\" (USD) INC","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0821914370.USD":"贝莱德亚洲成长领袖A2","LU0287142896.SGD":"Fidelity China Focus A-SGD","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","SG9999001689.USD":"施罗德亚洲成长股票","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU1734074674.USD":"NINETY ONE GSF ASIA PACIFIC FRANCHISE \"A\"(USD) ACC","LU0029875118.USD":"TEMPLETON ASIAN GROWTH \"A\" INC"},"translate_title":"Is the home quick test that exploded in the flu season really that effective?","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"86618":0.6,"00241":0.9,"03690":1.95,"HMTD.SI":0.6,"MPNGY":1.95,"METmain":0.6,"06618":0.83},"content_text":"千亿市场博弈下爆火的居家快检，是救命神器还是踩坑陷阱？/文｜何阑伊编｜杨肖若出品｜商业秀图片来源｜由AI生成凌晨两点的北京，王女士抱着烧到39℃的孩子急得直跺脚。医院发热门诊数小时的长队、未知的交叉感染风险，让此时着急的她果断打开美团买药，下单了流感居家快检。2点40分采样盒敲门，5分钟搞定鼻拭子，清晨5点收到甲流阳性报告，线上问诊开方后，7点奥司他韦就送上门，孩子当天下午就退了烧。这场深夜育儿危机，被检测+问诊+送药的闭环，稳稳化解。而在千里之外的杭州，互联网从业者李先生却骂骂咧咧地躺了一周。发烧38.3℃恰逢项目冲刺，他怕耽误工作下单居家快检，阴性结果让他硬扛了两天。可高烧始终不退，等去医院确诊乙流时，早已错过48小时黄金用药期，最后只能请假卧床，项目进度也落了一大截。同样是美团买药的居家快检，有人夸它是“流感季救星”，有人觉得它会“耽误病情”。这个爆火的服务，在流感高发季搅动了整个医疗消费市场。中国疾控中心最新数据显示，目前全国共有17个省份流感活动处于高流行水平，其余省份处于中流行水平，门急诊就诊的流感样病例患者中流感病毒检测阳性率达到51%，未超过近三年最高水平。需求之下，平台订单量疯涨。据新京报报道，美团买药12月健康指数显示，华东和中部城市甲流指数仍处快速上升阶段。流感检测需求激增，近一周，美团买药居家快检服务订单量环比增长超60%，上海等核心城市订单创年内新高，亲子用户占了七成。除美团买药以外，阿里健康和京东健康也上线了类似服务，流程和时效相似，价格也几乎一样，首单价69.9元，差不多是院内检测价格的三分之一。据财新网报道，首都医科大学附属北京地坛医院（称“地坛医院”）联合京东健康于12月1日推出了“呼吸道病原3小时护士上门快速检验”服务。号称“3小时就能出报告，覆盖6种常见呼吸道病原体。”一边是缓解医疗挤兑的创新尝试，一边是频繁出现的检测误差，美团买药们力推的居家快检，真的有那么灵吗？01爆火的居家快检，戳中谁的刚需？居家快检之所以能在流感季杀出重围，本质上是精准踩中了三类人的核心需求，再加上政策和技术的双重加持，一度火爆出圈。对很多家长来说，省时、少折腾就是优势。有疾控相关数据显示，5-14岁孩子的流感阳性率远高于其他年龄组，孩子突发高烧，家长最怕的就是医院排队几小时，还可能交叉感染。好在居家快检主打30分钟送样、3-4小时出结果，这样的节奏刚好解决了很多家长的这个痛点。现在北京、上海还推出了护士上门采样服务，给老人小孩多了一层专业保障。对很多上班的打工人来说，居家快检也是不请假自救的首选。你想，互联网、金融行业从业者哪敢轻易请假。轻微发烧咳嗽，花个64.9到69.9元，也才不到医院费用的一半，3小时内就能完成检测，确诊后直接下单特效药，完全不耽误工作。一些数据也印证了这点，华东地区甲流药品订单周涨超80%，武汉更是涨了95%，玛巴洛沙韦订单直接翻倍，大多是快检确诊后的连带消费。从公共卫生角度看，它更像是个靠谱的医疗分流器。流感季医院发热门诊挤得水泄不通，大连某医院等候区甚至出现全员咳嗽的场景。而美团数据显示，过去近一年已有超50万人次通过平台完成居家检测，轻症患者不用往医院跑，确实很大程度上缓解了医疗挤兑。从检测试剂需求来看，10月初，平台与万孚健康、复星诊断等6家知名医疗器械品牌达成深度合作，目前甲乙流检测试剂覆盖率近90%。今年11月以来，甲乙流呼吸道检测试剂销量月环比增长超9倍。此外，美团买药的居家快检服务从原来的7个城市增加至包括北京、上海、广州、深圳、杭州等在内的13个城市，其中有8个重点城市在近期流感高发季的运力提升了近一倍。国家疾控的一些专家也认可这种模式，能早期发现感染者，减少聚集性传播。2024年12月2日，中国检验检测学会发布了《居家医学检验外送服务规范》（T/CITS 172—2024），这也是国内首个居家检测外送服务相关的团体标准。现在平台用的核酸检测灵敏度也接近医院水平，能精准区分甲流、乙流，可见技术和政策都给了支撑。02背后争议：假阴性，谁为这份便捷买单？但是，再方便的服务，背后也有不能忽视的风险。有业内人士称，居家快检终究替代不了医院的专业诊断，这些坑一定要避开。首先，最让人头疼的就是假阴性问题。操作不当更是放大误差的关键。不同品牌试剂要求天差地别，不同品牌试剂要求天差地别，有的要拭子深入鼻腔3cm旋转15秒，有的只写1cm，按后者操作的漏检率比前者高23%。普通用户没经过专业培训，拭子插得太浅、旋转时间不够，都可能会导致样本不足；更易被忽视的是判读细节，若超过说明书规定的20分钟再观察结果，假阳性概率会增加4倍。值得注意的是，即便是规范操作，居家快检的灵敏度仍有局限。一项纳入全球152个研究、超10万人次样本的荟萃分析显示，抗原自测在有症状感染者中敏感性仅为73%（即27%可能假阴性），在无症状感染者中敏感性更差，仅55%（即45%可能假阴性）。相比之下，医院的核酸检测因存在核酸扩增环节，准确率可达90%以上，被视为诊断金标准，能更精准地明确感染亚型，为用药提供科学依据。还有适用人群的局限性。国家疾控局提醒，儿童、老年人以及有慢性基础性疾病患者感染流感后，有发生重症或其他并发症的风险。出现持续高烧等症状时应及时就医，目前国内已有有效的治疗药物。12月19日，国家卫生健康委召开新闻发布会特别提醒，65岁以上的中老年人、3岁以下的儿童、孕妇、身体质量指数BMI大于30的肥胖者、有慢性基础病者，自身抵抗力较弱，是重症流感的高危人群，一旦出现突发高热、肌肉酸痛等流感症状，不要等待观察，发病48小时内应尽早就医。可总有人为了图方便，选居家快检，最后耽误了治疗。以上这类人就算快检阴性，症状持续也要立刻就医。另外，检测范围的局限与过度检测乱象并存，进一步加剧了健康风险。目前多数居家快检仅覆盖12种常见病原体，像合胞病毒、腺病毒等高发致病原均未纳入检测范围。更关键的是，检测阴性不代表没感染其他病毒，若将快检结果当成“最终诊断”，很可能错过其他疾病的治疗时机。此外，部分检测结果可能存在误导性，比如肺炎链球菌等是人体呼吸道常见定植菌，即使检测显示“检出（条件致病）”，也未必是当前症状的直接病因，需结合临床症状综合判断。另一个容易被忽视的问题是，居家检测后自行用药的风险极高。有医生提醒，甲流、乙流虽有特效药，但奥司他韦、玛巴洛沙韦等处方药的适用人群和用法用量有严格要求，比如玛巴洛沙韦暂不适用儿童、孕妇和哺乳期妇女；而腺病毒、鼻病毒等感染目前并无特效药，滥用抗病毒药或抗生素，不仅无效还可能损伤肝肾，或导致细菌耐药性增加。当便捷与精准失衡，当误操作、假阴性以及不规范用药可能叠加形成健康隐患，这份看似省心的居家快检，最终的风险成本，难道要由普通用户来买单？03千亿商业赛道，互联网巨头在抢什么？尽管居家快检争议不断，但因为流感、新冠等呼吸道疾病常态化，让这个赛道成了香饽饽，美团、京东健康、阿里健康等巨头，纷纷入局打得火热。从时间线上来看，各家互联网巨头官宣推出居家快检业务的节点基本都卡在2023年。目前行业形成了两种主流模式，一是美团买药的“自采送检”，靠即时配送网络实现“30分钟送样+3小时出结果”，主打便捷和性价比，近半数药店已经接入“1对1急送”。二是京东健康的“上门采样送检”，联合医院推出护士上门服务，样本直接送医院实验室，主打精准可靠。还有福州的医院推出“护士上门+公立医院检测”，让居家检测也能拿到医院报告。各家的价格战打得更是激烈。12联检的居家快检，平台补贴后才64.9到69.9元，而医院同类检测要200元左右。据一位接近京东健康的人士透露，居家快检业务本身仍处于亏损状态，基本是做一单亏几十块钱，离打平还有很大的缺口，但管理层给了相对充裕的空间，“在当下这个阶段，公司并不是太在意钱的事，还是希望用恰当的价格，让用户接受在家做检测，培养心智。”美团的公开数据也证明了这一点，甲乙流特效药订单大增，奥司他韦覆盖率稳定在98%以上，检测和购药形成了完美闭环。但值得注意的是，无论是美团还是京东，都为居家快检配置了线上问诊开方的服务。而从用户画像来看，使用居家快检的用户大多都是急性起病，且有明确诊断的具体需求，这和当前互联网诊疗中的慢病复诊患者完全是两个群体。但随着2024年底行业规范的出台，再加上检测试剂灵敏度提升、服务网点扩张，居家快检或许会越来越成熟。有业内人士预测，未来三年市场规模能突破千亿，除了呼吸道检测，还会拓展到慢病管理、女性健康、肿瘤早筛等领域。美团买药们推出的居家快检，确实是科技和市场需求催生的尝试，在一定程度上缓解了医疗挤兑、性价比高、省时省力，开辟了互联网医疗的新赛道。但工具好不好，关键看怎么用，如果说把它当成轻症初筛的辅助手段，它就能帮你省不少事。可要是把它当成替代医院的救命稻草，就可能踩坑。所以，有个底线要牢记，居家快检只能当补充，绝不能替代医院诊断。该自检，还是该就医，大家还是要根据自身情况及时决策。尤其是高危人群和重症患者，医院的专业诊疗，才最靠谱。希望大家都能理性看待居家快检这项服务，在便捷和谨慎之间，平安地度过这个流感季。“完”","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}